Corporate Fact Sheet 2H-2023

OVERVIEW

  • Developing novel uses and delivery forms of drugs for infectious diseases, rare disorders, mental health
  • Advancing clinical development of Bucillamine for infectious diseases (COVID-19) and ischemia reperfusion
  • Novel uses and delivery (Thin film, Patch) of Psilocybin
  • Robust patent portfolio(15 patents and patent applications)
  • Prioritize development efforts targeting FDA regulatory

incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)

PRODUCT PIPELINE

EXPECTED MILESTONES 2H-2023

Complete reformulation of Bucillamine IV for future studies in infectious diseases and ischemia-reperfusion

IND-enabling studies of Psilocybin Patch

Phase 1/2 study - Psilocybin in Methamphetamine Disorder at University of Wisconsin

Psilocybin oral thin film strip development

MDMA patch for research purposes

CONTACT INFOMATION

Revive Therapeutics Ltd.

82 Richmond Street East

Toronto, ON M5C 1P1

Tel: 1-888-901-0036

E-mail:info@revivethera.com

Website:revivethera.com

STRATEGIC PARTNERS

TEAM

Management

Michael Frank, Chairman & CEO

Carmelo Marrelli, CFO

Derrick Welch, COO, Psilocin Pharma

Scientific and Clinical

Dr. Kelly McKee, CSO Dr. Arshi Kizilbash, M.D.

Dr. Osnesmo Mpanju, Regulatory Affairs

Dr. John Fahy, MD, Clinical and Scientific Advisor

Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon

STOCK INFORMATION

Ticker:

CSE: RVV, OTCQB: RVVTF,

FRANKFURT: 31R

Share Price:

$0.035 (July 20, 2023)

52-week High / Low:

CAD $0.485 / $0.02

Shares Outstanding:

356,237,674

Market Cap:

CAD ~ 12,500,000

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Revive Therapeutics Ltd. published this content on 26 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 July 2023 11:41:40 UTC.